Compare IDEXX Laboratories, Inc. (IDXX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs VF Corp — how do they compare? IDEXX Laboratories, Inc. trades at $519.96 (market cap $40.43B), while VF Corp trades at $15.04 (market cap $5.71B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.1× VF Corp's market cap, and VF Corp pays a 2.48% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and VF Corp for 64 Days on average.
| IDXX | VFC | |
|---|---|---|
Market Cap | $40.43B | $5.71B |
Volume | 692,164 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $21.55 |
52-Week Low | $504.70 | $12.62 |
Typical Hold Time | 46 Days | 64 Days |
Enterprise Value | $41.32B | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
VFC trades at $15.00, up 4.31% today, showing recent volatility amid mixed earnings results. The stock maintains a bullish technical signal with strong moving average support, while fundamentals reveal declining revenue from $11.8B in 2022 to $9.5B in 2025 and negative net income of -$189.72M. Analyst consensus leans Hold with a $18.33 price target, representing 22% upside potential. Recent news highlights ongoing challenges with Vans brand performance despite strength in Outdoor segments.
VFC presents a turnaround opportunity with discounted valuation (P/S 0.61) but faces execution risks from brand-specific weaknesses. The company's deleveraging progress and dividend cut signal financial discipline, though sustained revenue growth remains critical for recovery. Near-term catalysts include Q3 2026 earnings and continued Outdoor segment momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
